We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Survival analysis of sentinel lymph node biopsy in rare malignant adnexal carcinomas.
- Authors
Elias, Marcus L.; Koptyev, Jonathan; Yan, Bernice Y.; Strunk, Andrew; Sharon, Victoria R.; Garg, Amit
- Abstract
Two-year and 5-year OS for patients who had undergone SLNB (the SLNB group) was 91.8% (95% CI 90.2-93.3) and 82.5% (95% CI 80.2-84.8) compared with 90.0% (95% CI 89.0-90.9) and 76% (95% CI 74.6-77.5%) in the patients who had not undergone SLNB (the non-SLNB group), respectively. In this study, we compared overall survival (OS) among patients with AC stratified by whether or not SLNB was performed. Dear Editor, Sentinel lymph node biopsy (SLNB) is an important staging tool for cutaneous malignancies. Among 9643 patients with AC, 5676 patients were included and there were data for lymph node examination for 5603 patients and of these 1265 (22.6%) underwent SLNB (Table 1).
- Subjects
SENTINEL lymph node biopsy; ADNEXAL diseases; SURVIVAL analysis (Biometry); CARCINOMA
- Publication
Clinical & Experimental Dermatology, 2023, Vol 48, Issue 9, p1044
- ISSN
0307-6938
- Publication type
Article
- DOI
10.1093/ced/llad155